Meta-Analysis
Copyright ©The Author(s) 2023.
World J Gastroenterol. Aug 21, 2023; 29(31): 4797-4808
Published online Aug 21, 2023. doi: 10.3748/wjg.v29.i31.4797
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart of database search and study inclusion. ACLD: Advanced chronic liver diseases.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Forest plots for the overall meta-analyses regarding the association between serum copeptin and transplant-free survival of patients with chronic liver diseases. 95%CI: 95% confidence interval.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Forest plots for the subgroup analyses regarding the association between serum copeptin and transplant-free survival of patients with chronic liver diseases. A: subgroup analysis according to study country; B: Subgroup analysis according to study design. 95%CI: 95% confidence interval.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Forest plots for the subgroup analyses regarding the association between serum copeptin and transplant-free survival of patients with chronic liver diseases. A: Subgroup analysis according to the diagnosis of the patients; B: Subgroup analysis according to the cutoffs of serum copeptin. 95%CI: 95% confidence interval.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Forest plots for the subgroup analyses regarding the association between serum copeptin and transplant-free survival of patients with chronic liver diseases. A: Subgroup analysis according to the follow-up durations; B: Subgroup analysis according to the study quality scores. 95%CI: 95% confidence interval.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Funnel plots for the publication bias underlying the meta-analysis regarding the association between serum copeptin and transplant-free survival of patients with chronic liver diseases. RR: Risk ratio.